1. Home
  2. RDI vs ELTX Comparison

RDI vs ELTX Comparison

Compare RDI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reading International Inc

RDI

Reading International Inc

SELL

Current Price

$1.82

Market Cap

49.0M

ML Signal

SELL

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

SELL

Current Price

$1.44

Market Cap

45.6M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RDI
ELTX
Founded
1937
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
45.6M
IPO Year
1994
2014

Fundamental Metrics

Financial Performance
Metric
RDI
ELTX
Price
$1.82
$1.44
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $13.00
AVG Volume (30 Days)
27.0K
★ 303.3K
Earning Date
11-16-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 60.76
39.29
EPS
★ N/A
N/A
Revenue
★ $202,988,000.00
$2,301,000.00
Revenue This Year
$15.10
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.94
$1.25
52 Week High
$2.41
$16.00

Technical Indicators

Market Signals
Indicator
RDI
ELTX
Relative Strength Index (RSI) 53.66 37.50
Support Level $1.64 $1.25
Resistance Level $2.13 $1.98
Average True Range (ATR) 0.12 0.19
MACD 0.03 0.00
Stochastic Oscillator 65.85 28.12

Price Performance

Historical Comparison
RDI
ELTX

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: